To exclude the possibility that the inhibition of NSCLC cell growth is not a consequence of ATV off-target effects, we employed another anti-cholesterol drug, Simvastatin, which showed comparable dose-dependent downward trend on tumor cell viability (Figure S3A). This evidence concerns the gene NBN and non-small cell lung carcinoma.